Quarterly tomorrow

Perhaps tomorrow's quarterly will shed some light on how Errol has spent his 30 working days this quarter.

There were no announcements during the quarter so I'm not expecting a lot tomorrow.

But I wonder if they will address:

* status of agitation (I suspect it's been stopped)
* bnc375 event (suspect it's not going to happen)
* the need for additional capital
* the progress of the (2nd) review they are completing with the New York investment Bank Greenhill & Co.

All of the above I've said previously is my opinion that it is just window dressing and they are desperately trying to buy time before they can announce their new compounds. And pivot to being a solely pre-clinical biotech.

How anyone could consider their current transparency anything less than opaque is beyond me.